HGH Fragment 176-191 - Enhanced Pharma - 2mg × 5 vials
Buy HGH Fragment 176-191 5mg in India — Enhanced Pharma Research Grade
HGH Fragment 176-191 - Lipolysis Without GH
→ View HGH Fragment 176-191 buying guide for IndiaC-terminal fragment of human growth hormone (residues 176-191). Studied for fat-loss and lipolysis research without the IGF-1 elevation, glucose effects, or growth-promoting actions of full hGH.
Order this product
Factory-sealed box: 2mg × 5 vials. Ready for immediate dispatch.
🚚 Pan-India delivery / Cash on Delivery available
Why researchers reach for HGH Fragment 176-191
Lipolysis without GH side-effects
Stimulates fat breakdown without elevating IGF-1, affecting glucose, or causing the joint and water-retention effects of full hGH.
Beta-3 adrenergic upregulation
Increases expression of β3-adrenergic receptors on adipocytes - the receptor pathway responsible for catecholamine-driven fat oxidation.
Lipogenesis inhibition
Reduces new fat-tissue formation alongside the lipolytic action - addressing both halves of the adipose-balance equation.
Cartilage support
Australian TGA approved as iTRAM for intra-articular knee osteoarthritis - emerging interest in cartilage and joint repair models.
Community Insights
Self-reported by pep-pedia.org users and published research summaries. Not clinical evidence.
How HGH Fragment 176-191 Works
Beta-3 receptor upregulation
HGH 176-191 increases β3-adrenergic receptor expression on adipocytes - the receptor that drives catecholamine-induced lipolysis.
Lipolysis stimulation
Acutely stimulates fat-tissue breakdown via receptor-independent mechanisms in addition to the β3 pathway.
Lipogenesis inhibition
Reduces new triglyceride formation - addressing fat balance from both directions while sparing the GH/IGF-1 axis entirely.
Mechanism summary sourced from pep-pedia.org and the published peptide research literature.
Stack It With
Pairs Well
CJC-1295 with DAC
Pairs targeted lipolysis with sustained GH/IGF-1 elevation - a popular body-composition research stack that doesn't double-up on the same axis.
Pairs Well
MOTS-C
Adds AMPK-driven mitochondrial fat oxidation to the β3 lipolytic signal - complementary metabolic-research targets.
Full Specifications
Frequently Asked Questions
How is HGH Fragment different from full hGH?
Full hGH activates GH receptors throughout the body - driving IGF-1 elevation, water retention, glucose changes, and growth effects. HGH 176-191 was engineered to retain the lipolytic C-terminal sequence while losing the GH-receptor binding - fat action, no growth signal.
Does it raise IGF-1?
No. Pep-pedia (citing the AOD-9604 development data covering ~900 trial participants) confirms HGH 176-191 does not increase IGF-1 levels. This is its key differentiator from GHRH analogues and GH itself.
Does it affect blood glucose?
No. Six clinical trials with the AOD-9604 form showed it does not impair glucose tolerance or insulin sensitivity - unlike full hGH, which can induce insulin resistance at therapeutic doses.
When is HGH Fragment typically dosed?
Most published protocols dose 250–500 mcg subcutaneously once daily, often in a fasted morning state to align with endogenous lipolytic rhythms. Pep-pedia notes the original clinical trials used oral dosing - the subcutaneous protocol is community-derived.
Is it WADA-prohibited?
Yes. Despite the absence of growth-promoting effects, HGH 176-191 is on the WADA prohibited list. Use is restricted to research models, not athletic enhancement.
Ready to order
HGH Fragment 176-191 - Enhanced Pharma
₹9,300 · 2mg × 5 vials · Lyophilized powder + BAC water · Pan-India delivery
Add to CartResearch Use Only
This product is intended solely for laboratory and research purposes. It is not intended for human consumption, therapeutic use, or as a food or drug product. By purchasing, you confirm that this product will be used exclusively for legitimate research applications.